Scailyte Raises 2.75 Million for Market Entry From Swisscom, ZKB
19.12.2018
Scailyte AG, which uses artificial intelligence to analyse complex cells individually, raised 2.75 million Swiss francs ($2.77 million) to bring its software to market in the first-quarter of 2019.
 Scailyte team members
|
 |
The Lucerne-based biotech startup's new investors include Swisscom Ventures and Zürcher Kantonalbank AG.
"With the support of strong partners like Swisscom Ventures and Zürcher Kantonalbank, we will grow to become pioneers and leaders in the fast emerging Single-Cell Analysis market, enabling the clinical application of single-cell data," Scailyte's chief executive officer Peter Nestorov said. The company's software can be used in biomedical research, drug discovery and precision diagnostics.
Single-cell analysis is tipped to be a key future technology by industry publications such as The Scientist, which ranked four types of single-cell analysis technology among this year's ten best innovations. Gathering information on a cellular level can help scientists understand biology better than than tissue-level sampling.
Scailyte, a spin-off from the Swiss Federal Institute of Technology in Zurich, won a 10,000-franc grant from Venture Kick and participated in Swizerland's federal Innosuisse Start-up Training program in 2017. The company conducted proof-of-concepts and clinical tests this year.
"We believe the single-cell analysis technology will bring precision medicine to the next level," said Dominique Megret, who heads Swisscom Ventures. Megret and Hemex AG's CEO Pascal Winnen will join Scailyte's board.